Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting
12. November 2019 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Mavrilimumab suppresses pathogenic immune responses in a validated in vivo model of medium and large vessel vasculitis - - Additional human ex vivo data support rationale for targeting GM-CSF in...